March 14, 2017
Shionogi said on March 13 that it will grant Canadian women’s health specialty firm Duchesnay exclusive rights to market and distribute Osphena (ospemifene), a post-menopausal vaginal atrophy drug, in the US and Canada. The exclusive rights enable Duchesnay to develop,...read more